Affordable Access

The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics

Biologics Targets & Therapy
Dove Medical Press
Publication Date
  • Review
  • Biology
  • Medicine
  • Pharmacology


An effective treatment for metastatic melanoma remains one of the most elusive goals in all of oncology. Several generations of therapeutic trials have yet to yield any agents that can significantly prolong survival for widespread disease. Despite this disheartening history, our understanding of the biology and molecular genetics of melanoma hold the promise of a new era of molecular targets. One pathway that appears to be universally activated in and critically needed for melanoma growth is the Ras/mitogen activated protein (MAP) kinase signaling cascade. Since the enzymatic functions of the signaling partners are well characterized, this pathway offers many potential “druggable” candidates including Braf, Mek and Ras itself. In this review, we describe this pathway in the context of melanoma tumorigenesis and discuss some of the current relevant pharmacologic treatments and clinical trials.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

The RAS/mitogen activated protein (MAP) kinase pat...

on Biologics : targets & therapy December 2007

Ras-GTP dimers activate the Mitogen-Activated Prot...

on Proceedings of the National Ac... Jun 30, 2015

Advances in the development of cancer therapeutics...

on Clinical Cancer Research Jun 15, 2008

Reactivation of mitogen-activated protein kinase (...

on Journal of Biological Chemistr... Aug 10, 2012
More articles like this..